Clinical Trial Search

Primary: Incidence of Surgical Site Infection (SSI) Relating to Intramedullary Nailing for Fixation of Diaphyseal Femoral and Tibial Fractures — 26; 195 Participants

Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants

Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples

Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants

Primary: Surgeon Attitudes About Using Intra-wound Antibiotics for Spine Surgery — 9; 36; 46 Participants

Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants

Primary: Measurement of Change in Cutibacterium Acnes — 3; 8; 3; 2 Participants — p=0.004

Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants

Primary: Clinical Success at 6 Months — 18; 9; 3 Participants

Primary: Study Design Feasibility for Preoperative ICG Perfusion Rate as a Predictability Factor for Infection: Measured as Percentage of Patients With Analyzable Data — 0…

Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants

Primary: Unbound Cefazolin Concentration in Skeletal Muscle — 3.22; 5.84 µg/ml/kg

Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants

Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants

Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants

Primary: Positive Cultures — 7; 7 cultures

Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants

Primary: Number of Participants With Tissue Samples Identified With Bacterial DNA According to Highly Sensitive Bacterial Assays — 10; 24; 20 Participants

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL

Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 20; 27; 6; 9 Participants

Primary: Incidence of Surgical Site Infection During the Post-operative Follow-up Period — 0; 0; 0 participants

Primary: Number of Participants With Total Wound Infections — 4; 9 participants — p==0.12

Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68

Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds

Primary: Presence of Bacteria Within Shoulder Culture Using Incisional Prep vs. no Prep — 11; 9; 6 Participants — p=0.275

Primary: PDUS — 28.68; 19.52; 12.17 units on a scale — p=<0.0001

Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001